Refractory Angina Pipeline Insight 2025: Novel Regenerative, Device-Based, and Pharmacologic Therapies Target an Unmet Cardiovascular Need | DelveInsight

DelveInsight's "Refractory Angina - Pipeline Insight, 2025" highlights a growing and high-need cardiovascular segment. Refractory angina (RA), characterized by persistent chest pain unresponsive to standard revascularization and optimal medical therapy, impacts thousands globally, often resulting in poor quality of life and frequent hospitalizations. Despite its disabling burden, RA has limited therapeutic options, with conventional treatments offering modest benefits. However, the pipeline is now evolving to include regenerative therapies, neuromodulation devices, and novel vasodilators aiming to restore myocardial perfusion and reduce ischemia.

The 2025 pipeline features more than 3 active candidates, including CellProthera's ProtheraCytes, an autologous stem cell therapy currently in Phase II; Neovasc Reducer, a CE-marked coronary sinus reducer that is being evaluated in the U.S.; and Rexlemestrocel-L by Mesoblast, a mesenchymal stem cell product in advanced stages. These therapies target mechanisms beyond traditional pharmacology-ranging from promoting angiogenesis to modulating pain pathways-reflecting a shift in treating RA as both a perfusion and neuropathic condition. Several other agents like IMR-687 (Imara) and Ronopterin (NBP Pharma) are under investigation for microvascular angina and nitric oxide modulation.

Additionally, the therapeutic ecosystem is being reshaped by digital diagnostics and patient stratification tools, enabling more personalized approaches to RA management. Fast-track designations by the FDA for severe ischemic heart conditions, combined with a rising number of multinational clinical trials, are accelerating development timelines. The convergence of cell therapy, precision devices, and novel anti-ischemic agents signals a hopeful future for refractory angina patients who previously had few viable treatment paths.

Interested in learning more about the current treatment landscape and the key drivers shaping the refractory angina pipeline? Click here: https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Refractory Angina Pipeline Report
• DelveInsight's refractory angina pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for refractory angina treatment.
• The leading refractory angina companies include Caladrius Biosciences, Inc., Angionetics Inc., mbria Pharmaceuticals, Xylocor Therapeutics, Inc., and others are evaluating their lead assets to improve the refractory angina treatment landscape.
• Key refractory angina pipeline therapies in various stages of development include XC001, Generx (Ad5FGF-4), and others.
• Neovasc has received FDA approval of its Investigational Device Exemption (IDE) for the COSIRA‐II trial (Coronary Sinus Reducer for Treatment of Refractory Angina), a 380‐patient, randomized, double‐blind, sham-controlled pivotal study in the U.S. and Canada. Enrollment is expected to complete by end of 2023, with the aim of supporting U.S. FDA marketing authorization of the Reducer device.

Request a sample and discover the recent breakthroughs happening in the refractory angina pipeline landscape at https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Refractory Angina Overview
Refractory angina is a chronic and debilitating condition characterized by persistent chest pain due to inadequate blood supply to the heart, despite optimal medical therapy and revascularization procedures like angioplasty or bypass surgery. It is typically seen in patients with advanced coronary artery disease who continue to experience symptoms that significantly impact their quality of life.

Managing refractory angina remains a clinical challenge, as standard treatments often fail to provide relief. Emerging therapies focus on improving blood flow, reducing oxygen demand, or modifying pain perception. These include enhanced external counterpulsation (EECP), spinal cord stimulation, gene therapy, and novel pharmacological agents under investigation.

Find out more about refractory angina medication at https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Refractory Angina Treatment Analysis: Drug Profile
XC001: XyloCor Therapeutics
XC001, developed by XyloCor Therapeutics, is an investigational gene therapy aimed at treating patients with refractory angina who are no longer eligible for standard interventions like PCI or bypass surgery and have exhausted pharmacologic options. These patients often suffer from severe chest pain triggered by minimal physical activity, leading to inactivity, worsening comorbidities, and a significantly reduced quality of life. XC001 is designed to stimulate the growth of new coronary blood vessels to improve blood flow to underperfused areas of the heart, potentially reducing symptoms and improving daily functioning. Supported by preclinical and clinical evidence, the therapy is currently in Phase I/II development, with an active IND application and completed trial enrollment.

Learn more about the novel and emerging refractory angina pipeline therapies at https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Refractory Angina Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Refractory Angina Pipeline Report
• Coverage: Global
• Key Refractory Angina Companies: Caladrius Biosciences, Inc., Angionetics Inc., mbria Pharmaceuticals, Xylocor Therapeutics, Inc., and others.
• Key Refractory Angina Pipeline Therapies: XC001, Generx (Ad5FGF-4), and others.

To dive deep into rich insights for drugs used for refractory angina treatment, visit: https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Refractory Angina Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Refractory Angina Pipeline Therapeutics
6. Refractory Angina Pipeline: Late-Stage Products (Phase III)
7. Refractory Angina Pipeline: Mid-Stage Products (Phase II)
8. Refractory Angina Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.